6564 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Enimmune Corp. engages in the research, development of new drugs. Its products include EV71, Japanese encephalitis virus, EV71+CA16 bivalent, tetanus toxoid adsorbed, influenza, AH1N1, and pneumococcal vaccines. The company operates pharmaceutical outlets. Enimmune was founded on January 10, 2014 and is headquartered in Taipei, Taiwan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
6564 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company